ClinicalTrials.Veeva

Menu

The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes (ACME)

A

AdventHealth Translational Research Institute

Status

Completed

Conditions

Type 1 Diabetes

Treatments

Other: DEXA
Other: CGM
Other: Dietary counseling
Other: Whole room calorimeters
Other: MRI

Study type

Observational

Funder types

Other

Identifiers

NCT03379792
TRIMDFH 1144866

Details and patient eligibility

About

The purpose of this study is to measure the metabolic phenotype of a range of body weights in individuals with and without type 1 diabetes.

Enrollment

32 patients

Sex

All

Ages

19 to 30 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Males and females, 19 to 30 years of age, inclusive.

  2. Type 1 Diabetes Cohort:

    1. Diagnosis of type 1 diabetes for greater than 1 year at screening.
    2. Hemoglobin A1c 6.5-13% or

    Control Cohort Without Diabetes:

    a. Healthy individuals without diabetes matched to T1D cohort by BMI and gender

  3. Able to provide informed consent.

  4. BMI 18-39.9 kg/m^2

Exclusion criteria

  1. Type 2 diabetes
  2. History or presence of cardiovascular disease (unstable angina, myocardial infarction or coronary revascularization within 6 months, clinically significant abnormalities on EKG, presence of cardiac pacemaker, implanted cardiac defibrillator)
  3. Liver disease (AST or ALT >2.5 times the upper limit of normal), history of hepatitis
  4. Kidney disease (creatinine >1.6 mg/dl or estimated glomerular filtration rate (GFR)<60 ml/min)
  5. Dyslipidemia, including triglycerides >800 mg/dl, LDL >200 mg/dl
  6. Anemia (hemoglobin <12 g/dl in men, <11 g/dl in women)
  7. Thyroid dysfunction (suppressed thyroid-stimulating hormone (TSH), elevated TSH <10 µIU/ml if symptomatic or elevated TSH >10 µIU/ml if asymptomatic)
  8. Uncontrolled hypertension (BP >160 mmHg systolic or > 100mmHg diastolic)
  9. History of cancer within the last 5 years (skin cancers, with the exception of melanoma, may be acceptable).
  10. Initiation or change in hormone replacement therapy within the past 3 months (including, but not limited to thyroid hormone, birth control or estrogen replacement therapy)
  11. History of organ transplant
  12. History of HIV, active Hepatitis B or C, or Tuberculosis
  13. Pregnancy, lactation or 6 months postpartum from screening visit
  14. History of major depression
  15. Psychiatric disease prohibiting adherence to study protocol
  16. History of eating disorders
  17. Cushing's disease or syndrome
  18. History of bariatric surgery
  19. Tobacco use within the past 3 months
  20. History of drug or alcohol abuse (≥3 drinks per day) within the last 5 years
  21. Use of oral or injectable anti-hyperglycemic agents (except insulin)
  22. Current use of beta-adrenergic blocking agents
  23. Use of antibiotics within the past 3 months
  24. Weight >450 lbs (This is DEXA table weight limit)
  25. Metal implants (pace-maker, aneurysm clips) based on Investigator's judgment at screening
  26. Unable to participate in MRI or magnetic resonance spectroscopy (MRS) assessment based on Investigator's judgment at screening
  27. Participants with strict dietary concerns (e.g. vegetarian or kosher diet, multiple food allergies, or allergies to food we will provide them during the study)
  28. Gastrointestinal disorders including: inflammatory bowel disease or malabsorption, swallowing disorders, suspected or known strictures, fistulas or physiological/mechanical GI obstruction, history of gastrointestinal surgery, Crohn's disease or diverticulitis.
  29. Presence of any condition that, in the opinion of the investigator, compromises participant safety or data integrity or the participant's ability to complete study visits

Trial design

32 participants in 6 patient groups

Type 1 Diabetes: BMI Classified as Lean
Description:
Participants with type 1 diabetes with a BMI between 18.0-24.9 kg/m\^2.
Type 1 Diabetes: BMI Classified as Overweight
Description:
Participants with type 1 diabetes with a BMI between 25.0-29.9 kg/m\^2.
Type 1 Diabetes: BMI Classified as Obese
Description:
Participants with type 1 diabetes with a BMI between 30.0-39.9 kg/m\^2.
Control: BMI Classified as Lean
Description:
Control participants without diabetes with a BMI between 18.0-24.9 kg/m\^2.
Control: BMI Classified as Overweight
Description:
Control participants without diabetes with a BMI between 25.0-29.9 kg/m\^2.
Control: BMI Classified as Obese
Description:
Control participants without diabetes with a BMI between 30.0-39.9 kg/m\^2.

Trial documents
2

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems